Live feed07:00:00·701dPRReleasevia QuantisnowVoydeya approved in Canada as add-on therapy to ravulizumab or eculizumab for adults with the rare disease PNH who have residual hemolytic anemia due to extravascular hemolysisByQuantisnow·Wall Street's wire, on your screen.AZN· AstraZeneca PLCHealth Care
